IP Library Granted Patent US 9,334,313
Granted Patent B2
US 9,334,313 · App. 14/293,967 · Granted May 10, 2016

Proteins and nucleic acids from meningitis/sepsis-associated

Inventors: Vega Masignani (Siena, IT); Danilo Gomes Moriel (Monteriggioni, IT); Francesco Berlanda Scorza (Trento, IT); Nathalie Norais (Siena, AT); Maria Rita Fontana (Siena, IT); Mariagrazia Pizza (Siena, IT); Laura Serino (Monticiano, IT); Herve Tettelin (Gaithersburg, MD)
Assignee: GlaxoSmithKline Biologicals SA
C07K14/245A61K39/0258A61K39/00A61K2039/505A61K2039/523
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,334,313
App. No.
14/293,967
Granted
May 10, 2016
Kind
B2
Abstract

Disclosed herein are various open reading frames from a strain of E. coli responsible for neonatal meningitis (MNEC), and a subset of these that is of particular interest for preparing compositions for immunizing against MNEC infections.

Claims (6)

1. A method of inducing an immune response in a subject comprising administering to the subject a polypeptide comprising: (a) an amino acid sequence having at least 95% sequence identity to SEQ ID NO: 810; (b) a fragment of SEQ ID NO: 810, wherein the fragment of SEQ ID NO: 810 comprises at least 20 consecutive amino acids from SEQ ID NO: 810 and the fragment is a B-cell epitope for extra intestinal pathogenic E.coli (ExPEC) and meningitis associated E.coli (MNEC); or (c) an amino acid sequence having at least 95% sequence identity to SEQ ID NO: 810 and including a fragment of at least 20 consecutive amino acids from SEQ ID NO: 810 that includes a B-cell epitope of the amino acid sequence of SEQ ID NO: 810.

2. The method of claim 1 , wherein the immune response is a protective immune response against an ExPEC infection.

3. The method of claim 1 , wherein the immune response is a protective immune response against an MNEC infection.

4. The method of claim 1 , wherein the polypeptide is administered as a pharmaceutical composition in admixture with a pharmaceutically acceptable carrier.

5. The method of claim 1 , wherein two are more polypeptides comprising (a), (b), or (c) are administered to the subject.

6. The method of claim 1 , wherein the polypeptide is administered as a composition further comprising an adjuvant.

Assignments (3)
CHANGE OF NAME Recorded Nov 8, 2018
From: NOVARTIS VACCINES AND DIAGNOSTICS S.R.L.
To: GLAXOSMITHKLINE VACCINES S.R.L.
Reel/Frame 047485/0735 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 8, 2018
From: MASIGNANI, VEGA; MORIEL, DANILO GOMES; BERLANDA SCORZA, FRANCESCO; NORAIS, NATHALIE; FONTANA, MARIA RITA; PIZZA, MARIAGRAZIA; SERINO, LAURA
To: NOVARTIS VACCINES & DIAGNOSTICS SRL.
Reel/Frame 047485/0884 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 8, 2018
From: TETTELIN, HERVÉ
To: J. CRAIG VENTER INSTITUTE
Reel/Frame 047486/0370 →
Continuity (4)
Division 11884812
Provisional Application 60654632 · Feb 18, 2005
Provisional Application 60712720 · Aug 29, 2005
Related Publication 20140356389A1 · Dec 4, 2014